Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by airflow limitation and chronic airway inflammation. The treatment of COPD is based on conservative and medicinal approaches aimed at reducing symptoms, improving patients’ quality of life, and slowing disease progression. This article discusses key methods of treating COPD, including bronchodilators, inhaled corticosteroids, and oxygen therapy.

COPD, bronchodilators, inhaled corticosteroids, oxygen therapy, treatment.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: https://goldcopd.org

Barnes, P. J., & Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. European Respiratory Journal, 33(5), 1165-1185. DOI: 10.1183/09031936.00128008

Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Rennard, S. I., & Baker, J. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. European Respiratory Journal, 31(2), 416-469. DOI: 10.1183/09031936.00099306

O'Donnell, D. E., Hernandez, P., Kaplan, A., et al. (2008). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Canadian Respiratory Journal, 15(Suppl A), 1A-8A.

Wedzicha, J. A., & Seemungal, T. A. (2007). COPD exacerbations: defining their cause and prevention. The Lancet, 370(9589), 786-796. DOI: 10.1016/S0140-6736(07)61382-8

Calverley, P. M. A., Anderson, J. A., Celli, B., et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine, 356(8), 775-789. DOI: 10.1056/NEJMoa063070

Rabe, K. F., Watz, H. (2017). Chronic obstructive pulmonary disease. The Lancet, 389(10082), 1931-1940. DOI: 10.1016/S0140-6736(17)31222-9